AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

Liposomal Formulation of Combinational Antibiotics

Summary: Researchers at Purdue University have developed a new liposomal formulation of combinational antibiotics for the treatment of respiratory infections. This new formulation incorporates two synergistic antibiotics to enable maximum bacteria killing against resistant pathogens while significantly reducing irritation to the respiratory tract.

Technology Benefits: Maximum bacteria killing against resistant pathogensReduce resistance development

Technology Application: Treatment of respiratory infectionsEradication of Pseudomonas aeruginosa

Detailed Technology Description: Qi ZhouZhou Research Lab

Countries: United States

Application No.: None

*Abstract: None

*Background: Liposomal formulations have been developed for single drugs such as ciprofloxacin but not for combinational antibiotics. Liposomal formulations have shown significant less irritation to the respiratory tract and much better safety in previous clinical trials. Developing liposomal formulations for combinational antibiotics might be beneficial for the treatment of respiratory infections.

*IP Issue Date: None

*IP Type: Provisional

*Stage of Development: Concept validated through theory, simulation, or models

*Web Links: Purdue Office of Technology CommercializationPurdue Innovation and EntrepreneurshipQi ZhouZhou Research Lab

Country/Region: USA

For more information, please click Here